Identification of goals and barriers from families considering peanut oral immunotherapy

Andrea Chaves Blackman MD1,2, Aikaterini Anagnostou, MD, PhD1,2

(1) Baylor College of Medicine, Texas Children's Hospital, Department of Pediatrics, Section of Immunology, Allergy and Rheumatology, Houston, TX, (2) Texas Children's Hospital, Department of Pediatrics, Section of Immunology, Allergy and Rheumatology, Houston, TX, TX, USA

Abstract Poster:
Title: Identification of goals and barriers from families considering peanut oral immunotherapy
Poster Number: 437
Abstract Title: Identification of goals and barriers from families considering peanut oral immunotherapy
Day: March 15th, 2020
Time: 9:45-10:45 a.m.
Primary Funding Mechanism: Self-funded

Rationale
- Peanut allergy has become an important health issue. It can be the cause of severe reactions triggering significant anxiety for the allergic individual especially with regards to the risk of accidental exposures.
- Peanut Oral Immunotherapy (POIT) is a recent developed treatment approach that has been shown to be effective in multiple research studies and has been associated with an acceptable safety profile. This treatment modality has just become available with FDA approval.

Methods
- The aim of our study was to obtain an accurate assessment of goals of treatment as well as concerns and barriers from families considering POIT in either the research or clinical setting.
- Patients were recruited from the allergy clinics at Texas Children’s hospitals. Parents of peanut – allergic children who expressed an interest in POIT were offered the opportunity to undergo a separate consultation dedicated to discussing POIT only.
- Families of current ongoing research trial children were excluded from participation as well as patients who had a history of uncontrolled asthma, severe allergic rhinitis, esophagitis, underlying immune deficiencies, or other food allergies.

Results
- **Common Questions from Families Considering POIT by Topic**
  - **Efficacy**: How long does it take to desensitize?
  - **Safety**: How long is the longest time needed to reach maintenance?
  - **Support**: What if the daily dosage is skipped or forgotten?
  - **Eligibility**: Is there a better age to start OIT?
  - **Benefits and Goals**: Are children with all levels of specific IgE to peanut included?
  - **Eligibility**: If my child has a high specific IgE level to peanut, will it be more difficult to achieve desensitization?
  - **Eligibility**: Is there a potential cross desensitization between peanut/tree nuts?
  - **Eligibility**: If my child is doing well from his/her peanut allergy? Do we still need to carry an epinephrine auto-injector after reaching maintenance?
  - **Eligibility**: Does it make a difference being only allergic to peanut or having multiple food allergies?

Discussion
- **Common Questions from Families Considering POIT by Topic**
  - **Efficacy**: How long does it take to desensitize?
  - **Safety**: How long is the longest time needed to reach maintenance?
  - **Support**: What if the daily dosage is skipped or forgotten?
  - **Eligibility**: Is there a better age to start OIT?
  - **Benefits and Goals**: Are children with all levels of specific IgE to peanut included?
  - **Eligibility**: If my child has a high specific IgE level to peanut, will it be more difficult to achieve desensitization?
  - **Eligibility**: Is there a potential cross desensitization between peanut/tree nuts?
  - **Eligibility**: If my child is doing well from his/her peanut allergy? Do we still need to carry an epinephrine auto-injector after reaching maintenance?
  - **Eligibility**: Does it make a difference being only allergic to peanut or having multiple food allergies?
  - **Eligibility**: We want our child to be protected from severe reactions.
  - **Eligibility**: I want her/him to be able to go to parties without worrying.

Conclusions
- **Our study adds to the limited available data in this area and provides information that may be used as an initial platform for clinical consultations and shared decision-making in POIT.**
  - **Our study adds to the limited available data in this area and provides information that may be used as an initial platform for clinical consultations and shared decision-making in POIT.**
  - **Our study adds to the limited available data in this area and provides information that may be used as an initial platform for clinical consultations and shared decision-making in POIT.**
  - **Our study adds to the limited available data in this area and provides information that may be used as an initial platform for clinical consultations and shared decision-making in POIT.**
  - **Our study adds to the limited available data in this area and provides information that may be used as an initial platform for clinical consultations and shared decision-making in POIT.**
  - **Our study adds to the limited available data in this area and provides information that may be used as an initial platform for clinical consultations and shared decision-making in POIT.**

Poster Details
- Poster Number: 437
- Abstract Title: Identification of goals and barriers from families considering peanut oral immunotherapy
- Day: March 15th, 2020
- Time: 9:45-10:45 a.m.
- Primary Funding Mechanism: Self-funded